Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
ICON issues financial guidance for 2022 as the CRO giant eyes spike in revenue growth
This article discusses ICON’s forecast revenues for 2022 and includes a statement from Steve Cutler on ICON’s successes from 2021.
-
Sharing clinical trial results with paediatric participants
Kirsten Sherman Cervati contributes to this media article which discusses the considerations for returning results to paediatric participants.
-
In-Home Services: A patient-centric approach to improving recruitment and retention in clinical trials
Advances in wearables, telemedicine and remote monitoring technology along with the convenience of in-home visits were bound to make decentralised and hybrid clinical trials standard with enough time. However, the COVID-19 pandemic accelerated their adoption and now, even with the hope that the pandemic will soon be behind us, hybrid and decentralised models are poised to become viable solutions in clinical trial design because of their inherent agility, inclusivity and most importantly, patient centricity.
-
Combating antimicrobial resistance
Shelley McLendon, Vice President, Vaccines and Infectious Disease, discusses the use of novel diagnostics to help monitor for AMR outbreaks and reduce the overuse and misuse of antimicrobials.
-
The ecosystem overtakes the producers in pharma and life sciences
This article discusses the substantial number of significant acquisitions and mergers in the pharma and life sciences industry, and features ICON’s $12bn acquisition of PRA Health Sciences back in February.
-
Forging ahead with French and Irish business connections
ICON is awarded the Best Irish Company in France 2021, recognising the significant contribution our French colleagues have made to our business in France and globally.
-
The growing potential of neurological biomarkers as surrogate endpoints for accelerated drug development
This article by Dr. Peter Schueler explores how digital and liquid biomarkers are developing, and how they can impact the future of neurological studies.
-
ICON expands Accellacare Site Network
An article reporting on ICON's recent announcement that its Accellacare Site Network has entered new partnerships with six research sites across four countries, expanding its global footprint and capabilities.
-
